1. Indications and Usage
\nTreatment-Resistant Tuberculosis:
\nPretomanid is indicated as part of a three-drug regimen (BPaL: Bedaquiline, Pretomanid, and Linezolid) for the treatment of adult patients with extensively drug-resistant (XDR-TB), treatment-intolerant, or nonresponsive multidrug-resistant (MDR-TB) pulmonary tuberculosis.
\nNote: It is not indicated as a single agent or for latent tuberculosis infection.
\n2. Dosage and Administration
\nRoute of Administration:
\nFor Oral Use ONLY.
\nRecommended Dosage:
\nDose: 200 mg once daily.
\nDuration: The recommended treatment duration is 6 months (26 weeks).
\nAdministration: Administer with food to enhance absorption.
\nMonitoring:
\nBaseline and periodic monitoring of liver function, complete blood count (due to Linezolid), and ECG (due to Bedaquiline) is required during the combination regimen.
\n3. Mechanism of Action
\nNitroimidazole Antibiotic:
\nPretomanid is a first-in-class nitroimidazole antimicrobial.
\nBacterial Cell Death:
\nUpon entering the mycobacterial cell, it is reduced by the dehydrogenase enzyme (F420) to toxic metabolites. These metabolites inhibit the synthesis of mycolic acids (essential components of the bacterial cell wall) and generate reactive oxygen species, leading to bacterial death.
\n4. Safety and Warnings
\nHepatotoxicity:
\nPretomanid can cause severe liver injury (hepatitis). Baseline and monthly monitoring of liver enzymes (ALT, AST) and bilirubin is mandatory.
\nSerotonin Syndrome:
\nThere is a risk of serotonin syndrome when Pretomanid is used in combination with Linezolid (which has monoamine oxidase inhibitory activity). Patients should be monitored for symptoms like agitation, hallucinations, or rapid heart rate.
\nPregnancy:
\nPretomanid can cause fetal harm. It is contraindicated in pregnant women.
\n5. Adverse Reactions
\nMost Common:
\nHepatic: Hepatitis, elevated liver enzymes.
\nGastrointestinal: Nausea, vomiting, diarrhea.
\nHematologic: Anemia (often due to Linezolid in the regimen).
\nNeurologic: Peripheral neuropathy, headache, insomnia.
\n6. Drug Interactions
\nMetabolic Pathway:
\nPretomanid is metabolized primarily by the liver (CYP450 enzymes).
\nStrong CYP Inducers\/Inhibitors:
\nCo-administration with strong inducers (e.g., Rifampin, Carbamazepine) may decrease Pretomanid exposure. Strong inhibitors (e.g., Ketoconazole) may increase exposure.
\nSerotonergic Drugs:
\nCaution is advised when combining with other serotonergic agents due to Linezolid in the BPaL regimen.
\n7. Pharmaceutical Information
\nChemical Composition:
\nActive Ingredient: Pretomanid.
\nAppearance: White to off-white, film-coated tablets.
\nStorage: Store at controlled room temperature (15\u00b0C\u201330\u00b0C).<\/p>\n","protected":false},"excerpt":{"rendered":"
Brand Name: \u666e\u745e\u5c3c\u00ae\uff08Puruini\u00ae\uff09
\nGeneric Name: Pretomanid
\nStrength: 200mg per tablet, 26 tablets per box
\nManufacturer: Mylan Laboratories Limited\uff1bPackaged by Shenyang Hongqi Pharmaceutical Co.,Ltd.
\nMarketing Authorization Holder: Shenyang Hongqi Pharmaceutical Co.,Ltd.
\nApproval Date in China: Dec 03, 2024
\nRegistration Number: \u56fd\u836f\u51c6\u5b57HJ20240153
\nStorage: Sealed storage below 30\u2103, avoid light and moisture; keep out of reach of children<\/p>\n
Price&Cost:Contact Us now for the best price of Pretomanid \uff08Puruini\uff09<\/p>\n","protected":false},"featured_media":3730,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[27],"product_tag":[],"class_list":["post-3729","product","type-product","status-publish","has-post-thumbnail","product_cat-tablets","first","instock","shipping-taxable","product-type-simple"],"yoast_head":"\n